247 related articles for article (PubMed ID: 34362187)
1. Potential Diagnostic Approaches for Prediction of Therapeutic Responses in Immune Thrombocytopenia.
Jolink AC; Nelson VS; Schipperus MR; Amini SN; Vidarsson G; van der Schoot CE; Porcelijn L; de Haas M; Kapur R
J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362187
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).
Kapur R; Aslam R; Speck ER; Rebetz JM; Semple JW
Platelets; 2020; 31(3):399-402. PubMed ID: 31146647
[TBL] [Abstract][Full Text] [Related]
3. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
Alvarez Román MT; Fernández Bello I; Arias-Salgado EG; Rivas Pollmar MI; Jiménez Yuste V; Martín Salces M; Butta NV
Thromb Haemost; 2014 Jul; 112(1):65-72. PubMed ID: 24500066
[TBL] [Abstract][Full Text] [Related]
4. Increased microvesicle-associated thrombin generation in patients with immune thrombocytopenia after initiation of thrombopoietin receptor agonists.
Garabet L; Ghanima W; Hellum M; Sandset PM; Bussel JB; Tran H; Henriksson CE
Platelets; 2020; 31(3):322-328. PubMed ID: 31280643
[TBL] [Abstract][Full Text] [Related]
5. Platelet and immune characteristics of immune thrombocytopaenia patients non-responsive to therapy reveal severe immune dysregulation.
Monzón Manzano E; Álvarez Román MT; Justo Sanz R; Fernández Bello I; Hernández D; Martín Salces M; Valor L; Rivas Pollmar I; Butta NV; Jiménez Yuste V
Br J Haematol; 2020 Jun; 189(5):943-953. PubMed ID: 31945798
[TBL] [Abstract][Full Text] [Related]
6. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
Kolonić SO; Patekar MB; Milunović V
Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
[TBL] [Abstract][Full Text] [Related]
7. Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists.
Garabet L; Ghanima W; Rangberg A; Teruel-Montoya R; Martinez C; Lozano ML; Nystrand CF; Bussel JB; Sandset PM; Jonassen CM
Platelets; 2020; 31(2):198-205. PubMed ID: 30885035
[TBL] [Abstract][Full Text] [Related]
8. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production.
Nugent D; McMillan R; Nichol JL; Slichter SJ
Br J Haematol; 2009 Sep; 146(6):585-96. PubMed ID: 19466980
[TBL] [Abstract][Full Text] [Related]
9. Mouse Models for Immune-Mediated Platelet Destruction or Immune Thrombocytopenia (ITP).
Neschadim A; Branch DR
Curr Protoc Immunol; 2016 Apr; 113():15.30.1-15.30.13. PubMed ID: 27038460
[TBL] [Abstract][Full Text] [Related]
10. CD4+CD25+Foxp3+ regulatory T cells in the pathophysiology of immune thrombocytopenia.
Nishimoto T; Kuwana M
Semin Hematol; 2013 Jan; 50 Suppl 1():S43-9. PubMed ID: 23664516
[TBL] [Abstract][Full Text] [Related]
11. Chronic immune thrombocytopenia in a child responding only to thrombopoietin receptor agonist.
Osman ME
Sudan J Paediatr; 2012; 12(2):60-4. PubMed ID: 27493347
[TBL] [Abstract][Full Text] [Related]
12. Megakaryocyte- and Platelet-Derived Microparticles as Novel Diagnostic and Prognostic Biomarkers for Immune Thrombocytopenia.
Wang W; Zuo B; Wang Y; Li X; Weng Z; Zhai J; Wu Q; He Y
J Clin Med; 2022 Nov; 11(22):. PubMed ID: 36431253
[TBL] [Abstract][Full Text] [Related]
13. The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura.
Gernsheimer TB
Hematology Am Soc Hematol Educ Program; 2008; ():219-26. PubMed ID: 19074086
[TBL] [Abstract][Full Text] [Related]
14. Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management.
Singh A; Uzun G; Bakchoul T
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33669423
[TBL] [Abstract][Full Text] [Related]
15. Romiplostim as a treatment for immune thrombocytopenia: a review.
Chalmers S; Tarantino MD
J Blood Med; 2015; 6():37-44. PubMed ID: 25632241
[TBL] [Abstract][Full Text] [Related]
16. Immune Thrombocytopenia: Recent Advances in Pathogenesis and Treatments.
Audia S; Mahévas M; Nivet M; Ouandji S; Ciudad M; Bonnotte B
Hemasphere; 2021 Jun; 5(6):e574. PubMed ID: 34095758
[TBL] [Abstract][Full Text] [Related]
17. Immune thrombocytopenia (ITP): Pathophysiology update and diagnostic dilemmas.
LeVine DN; Brooks MB
Vet Clin Pathol; 2019 Oct; 48 Suppl 1():17-28. PubMed ID: 31538353
[TBL] [Abstract][Full Text] [Related]
18. Sialic acid and platelet count regulation: Implications in immune thrombocytopenia.
Lee-Sundlov MM; Rivadeneyra L; Falet H; Hoffmeister KM
Res Pract Thromb Haemost; 2022 Mar; 6(3):e12691. PubMed ID: 35425875
[TBL] [Abstract][Full Text] [Related]
19. Emerging Concepts in Immune Thrombocytopenia.
Swinkels M; Rijkers M; Voorberg J; Vidarsson G; Leebeek FWG; Jansen AJG
Front Immunol; 2018; 9():880. PubMed ID: 29760702
[TBL] [Abstract][Full Text] [Related]
20. Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content.
Revilla N; Corral J; Miñano A; Mingot-Castellano ME; Campos RM; Velasco F; Gonzalez N; Galvez E; Berrueco R; Fuentes I; Gonzalez-Lopez TJ; de la Morena-Barrio ME; Gonzalez-Porras JR; Vicente V; Lozano ML
Platelets; 2019; 30(6):743-751. PubMed ID: 30296193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
